What CROs Cite as Their Top Clinical Trial Challenges and How They Plan to Overcome Them in 2025
In a rapidly evolving clinical research landscape, there is a greater need now more than ever for pharma and biotech …
All Posts
Discovery of Novel Longevity Therapeutics that Target Mitochondrial Enzymes
Researchers at CCM Biosciences, a New Jersey-based biopharmaceutical company, have reported the discovery of first-in-class compounds designed to restore the …
Merck KGaA Adopts Quris-AI’s Organ-On-Chip Platform for Preclinical Drug Safety Testing
Merck KGaA has integrated Quris-AI’s Bio-AI platform into its drug development pipeline to evaluate small molecule drug candidates for safety …
PostEra and Pfizer Expand $610M Partnership for AI-Driven ADC Development
PostEra, Boston biotech specializing in AI-driven drug discovery, announced an expansion of its collaboration with Pfizer, increasing the total partnership …
Tempus and Genialis Partner on RNA-Based Biomarker Algorithms
Tempus AI has partnered with Genialis to develop RNA-based biomarker algorithms aimed at improving cancer diagnostics and treatment outcomes. This …
Novo Nordisk and Valo Health Expand AI Collaboration for Cardiometabolic Drug Discovery
Novo Nordisk has deepened its partnership with Valo Health, increasing the scope of their collaboration to include up to 20 …
Recursion Advances Two Investigational Oncology Drugs to Clinical Trials
Recursion Pharmaceuticals announced the progression of two investigational oncology drugs, REC-3565 and REC-4539, into clinical trials, targeting critical unmet needs …
Neumora’s Kappa Opioid Antagonist Falters in Phase 3 Depression Trial
Neumora Therapeutics’ lead drug, navacaprant, failed to show efficacy in the Phase 3 "KOASTAL-1" trial for major depressive disorder (MDD), …
Profluent Unveils AI Model to Advance CRISPR-Cas Systems for Gene Editing
Profluent Bio, a Berkeley-based biotech founded in 2022, and funded with $44 million to date, has released an AI model …
Calico's Small Molecule eIF2B Activator Falls Short in ALS Trial
Calico, the Alphabet-backed biotech focused on aging and longevity, has encountered a hurdle in its efforts to develop treatments for …
Insilico Medicine Reports Positive Results from Phase I Trials of ISM5411, an AI-Designed Drug for Inflammatory Bowel Disease
Insilico Medicine announced favorable outcomes from two Phase I clinical trials of ISM5411, a gut-restricted PHD1/2 inhibitor designed for inflammatory …
Orbis Medicines Raises €90 Million For Oral Macrocycles, Backed by Novo Holdings and Eli Lilly
Denmark-based Orbis Medicines has raised €90 million ($93.2 million) in a Series A financing round to advance its development of …